Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
101/435
Matches for
“SteatoTest”
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
…the SteatoTest; the fatty liver index (FLI); regular abdominal ultrasound (AUS); and…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
…patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
…The median SteatoTest value was 0.13 in fasting controls; 0.16…
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
…FibroTest = 0.72 (0.63-0.79; P<0.0001); SteatoTest = 0…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…liver fibrosis (FibroTest) and steatosis (SteatoTest) in patients with type-2 diabetes…
-
[The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].
…61.9% and 93.9% for SteatoTest, 61.3% and 93.9…
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
…CAP was significantly correlated with SteatoTest, Fatty Liver Index (FLI), percentage of…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
…When the ability of the SteatoTest to identify patients with T2DM with…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
…liver disease fibrosis score, and SteatoTest and FibroTest scores were determined. ### Results…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
…In multivariate analysis, SteatoTest and FibroTest were significantly associated with sex, body…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
…The performances of the FibroTest, NashTest-2 and SteatoTest-2 were assessed…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
…0.85, 0.83-0.87, P<0.0001; SteatoTest for advanced…
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
…to be carrying severe steatosis. Steatotest score was significantly associated with BMI…
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
…examination), using non-invasive tests: SteatoTest, ActiTest and FibroTest. We compared the…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
…biopsy and blindly assessed FibroTest, SteatoTest-2 and NashTest-2. The secondary…
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
…test (comprising components including the SteatoTest, NashTest and FibroTest) through three randomized…
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
…An algorithm combining the percentage of CDT, FibroTest and SteatoTest permitted to…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
…Data collected included anthropometrics, biochemistry, adiponectin, SteatoTest™, NashTest™, FibroTest™, OWLiver® test and…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
…The Nash-FibroTest panel including FibroTest-T2D, SteatoTest-T2D and MashTest-T2D…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
…Blood samples (biochemistry, HOMA-IR, cytokine levels, steatotest) were collected at entry…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
…fibrosis reference and ActiTest and SteatoTest as quantitative estimates of inflammation and…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
…non-invasive biomarkers, FibroTest (FT), SteatoTest and NashTest, and to assess the…
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
…by hepatorenal index (HRI) and SteatoTest, whereas FibroTest was used to assess…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
…evaluated by biomarkers of steatosis (SteatoTest>0.38 as a surrogate for…
-
Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study. Key publication
…NAFLD's prevalence was 84% with a PPV for SteatoTest® of 85…
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
…FibroTest (BioPredictive) for the quantitative assessment of fibrosis; SteatoTest (BioPredictive) for the…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
…subjects. ### Methods Noninvasive blood tests (SteatoTest, NashTest, and FibroTest) were used to…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
…The SteatoTest was significantly lower among subjects engaging in any PA or…
-
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
…fibrosis by FibroTest, steatosis by SteatoTest, steatohapatitis by AshTest (alcoholic origin) and…
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
…index (r=0.46), the SteatoTest (r=0.39), homeostasis model assessment…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
…FibroMax® panels (i.e., SteatoTest®, FibroTest®, NashTest®, and ActiTest®) were determined from…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
…Liver function was assessed with standard serum biochemical markers, FibroTest, ActiTest, SteatoTest…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication
…We also measured the serum biomarkers included in the FibroMax® panels (SteatoTest…
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
…by the complex biochemical score SteatoTest. Serum cytokeratin-18 is a promising…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
### Background Although the FibroTest has been validated as a biomarker to determine…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered the gold standard for assessing histologic lesions…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
…databases (_N_ = 149,212) using SteatoTest-2 or a proxy. We performed…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
…As compared versus SteatoTest, NashTest, Fatty liver index, and Algorithm, the TyG…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
…NASH patients who received ACM showed a significant decrease in the SteatoTest…
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
…the FibroTest, SteatoTest and NashTest, from the Fibromax® panel. Among the main…
-
Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.
…The level of steatosis was defined using SteatoTest, moderate-severe NASH using…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
…All had hepatic MRI-PDFF, FibroScan/CAP, FibroTest/NashTest/SteatoTest, APRI, FIB…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
…noninvasively using FibroTest, ActiTest and SteatoTest. Predictive factors for SVR and their…
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Biomarkers of liver fibrosis. Review
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
**Background/Objectives**: Prior research has identified a significant association between heart disease…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
### Background & Aims There is controversy about the performance of noninvasive tests such…
-
Applicability and variability of liver stiffness measurements according to probe position.
### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
### Background & Aims Real-time shear wave elastography (SWE) is a new two…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
Screening studies of transient elastography and FibroTest in the general population.
-
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Key publication
### Background Haptoglobin bifucosylated tetra-antennary glycan have been identified in patients with…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
### Aim We evaluated the association between two medications that alter bioavailable androgen…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Noninvasive evaluation of NAFLD. Review
A common clinical concern in patients with NAFLD is whether they have…
-
Screening studies of transient elastography and FibroTest in the general population - Authors' reply.
-
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.
### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review
The correct identification of patients at increased risk of non-alcoholic steatohepatitis…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.
### Aim To investigate the diagnostic accuracy of acoustic radiation force impulse (ARFI…
-
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
### Purpose Transient elastography (FibroScan, [TE]) and serum fibrosis markers such as the…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
### Objective The 2019 _Standards of Medical Care in Diabetes_ suggested that patients…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
### Background No blood test has been shown to be effective in the…
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
### Background There is a clear need for better biomarkers of drug-induced…
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
### Objective Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review
Liver cirrhosis in Mexico is one of the most important causes of…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
### Objectives Extent of liver fibrosis is one of the most important factors…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
Showing the full result list. The page is server-rendered and not paginated.